Zenas BioPharma Inc. (ZBIO)
8.09
0.07 (0.87%)
At close: Jan 15, 2025, 11:35 AM
undefined% (undefined)
| Bid | 8.02 |
| Market Cap | 337.88M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -2.62 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.15 |
| Volume | 16,459 |
| Avg. Volume (20D) | 310,555 |
| Open | 7.98 |
| Previous Close | 8.02 |
| Day's Range | 7.79 - 8.14 |
| 52-Week Range | 7.50 - 26.25 |
| Beta | undefined |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclo...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 114
Stock Exchange NASDAQ
Ticker Symbol ZBIO
Website https://zenasbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ZBIO stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 301.98% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
